Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium
CAR-T方案作为侵袭性B细胞淋巴瘤二线、三线、四线及以上治疗的疗效:来自ABC联盟的真实世界证据
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017120
Wang, John S; Ellsworth, Brandon L; Melody, Megan; Epperla, Narendranath; Stephens, Deborah; Romancik, Jason; Cortese, Matthew; Bhansali, Rahul; Moyo, Tamara K; Kenkre, Vaishalee; Ollila, Thomas; Hess, Brian; Fitzgerald, Lindsey; Shouse, Geoffrey; Matasar, Matthew; Herr, Megan M; Davis, James; Jesme, Christy; Pelcovits, Ari R; Moreira, Jonathan; Lin, Adam Y; Ma, Shuo; Winter, Jane N; Danilov, Alexey V; Shah, Nirav N; Barta, Stefan K; Cohen, Jonathon B; Gordon, Leo I; Grover, Natalie; Karmali, Reem